CORRECTIONS

Pioglitazone may reduce cardiovascular events in high risk patients with prediabetes

Pioglitazone was incorrectly described as a PPAR-gamma inhibitor in this News story (*BMJ* 2016;352:i1029, doi:10.1136/bmj.i1029) when it is an agonist. The first sentence of the third paragraph should read that pioglitazone “improves insulin

sensitivity by stimulating [not inhibiting] peroxisome proliferator activated receptor gamma.”

Cite this as: *BMJ* 2016;352:i1087

© BMJ Publishing Group Ltd 2016